← Back to Screener
Fulgent Genetics, Inc. Common Stock (FLGT)
Price$16.13
Favorite Metrics
Price vs S&P 500 (26W)-33.16%
Price vs S&P 500 (4W)0.98%
Market Capitalization$479.83M
All Metrics
P/CF (Annual)21.90x
Book Value / Share (Quarterly)$35.78
P/TBV (Annual)0.83x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-19.52%
Cash Flow / Share (Quarterly)$-4.00
Price vs S&P 500 (YTD)-41.09%
Gross Margin (TTM)40.56%
Net Profit Margin (TTM)-18.75%
EPS (TTM)$-1.97
10-Day Avg Trading Volume0.48M
EPS Excl Extra (TTM)$-1.97
Revenue Growth (5Y)-5.21%
EPS (Annual)$-1.97
ROI (Annual)-5.43%
Gross Margin (Annual)40.56%
Net Profit Margin (5Y Avg)-3.51%
Cash / Share (Quarterly)$10.81
Revenue Growth QoQ (YoY)9.34%
ROA (Last FY)-4.99%
Revenue Growth TTM (YoY)13.83%
EBITD / Share (TTM)$-3.02
ROE (5Y Avg)6.23%
Operating Margin (TTM)-31.31%
Cash Flow / Share (Annual)$-4.00
P/B Ratio0.43x
P/B Ratio (Quarterly)0.73x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.34x
Net Interest Coverage (TTM)0.17x
ROA (TTM)-5.01%
EV / EBITDA (TTM)2.34x
EPS Incl Extra (Annual)$-1.97
Current Ratio (Annual)6.48x
Quick Ratio (Quarterly)5.16x
3-Month Avg Trading Volume0.43M
52-Week Price Return-14.67%
EV / Free Cash Flow (Annual)2.11x
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$31.49
P/S Ratio (Annual)1.49x
Asset Turnover (Annual)0.27x
52-Week High$31.04
Operating Margin (5Y Avg)-6.32%
EPS Excl Extra (Annual)$-1.97
CapEx CAGR (5Y)-8.45%
Tangible BV CAGR (5Y)78.18%
26-Week Price Return-29.17%
Quick Ratio (Annual)5.16x
13-Week Price Return-42.58%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)6.48x
Enterprise Value$432.427
Revenue / Share Growth (5Y)-9.74%
Asset Turnover (TTM)0.27x
Book Value / Share Growth (5Y)12.12%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-21.70%
Cash / Share (Annual)$10.81
3-Month Return Std Dev85.67%
Gross Margin (5Y Avg)50.41%
Net Income / Employee (TTM)$-0
ROE (Last FY)-5.44%
EPS Basic Excl Extra (Annual)$-1.97
P/FCF (TTM)18.25x
Receivables Turnover (TTM)4.20x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.97
Receivables Turnover (Annual)4.20x
ROI (TTM)-5.39%
P/S Ratio (TTM)1.49x
Pretax Margin (5Y Avg)-0.45%
Revenue / Share (Annual)$10.48
Tangible BV / Share (Annual)$31.49
Forward P/E88.46x
Price vs S&P 500 (52W)-44.50%
Year-to-Date Return-38.45%
5-Day Price Return7.66%
EPS Normalized (Annual)$-1.97
ROA (5Y Avg)5.59%
Net Profit Margin (Annual)-18.75%
Month-to-Date Return1.70%
Cash Flow / Share (TTM)$-1.20
EBITD / Share (Annual)$-3.02
Operating Margin (Annual)-31.31%
LT Debt / Equity (Annual)0.00x
P/CF (TTM)302.87x
ROI (5Y Avg)6.03%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-1.97
P/TBV (Quarterly)0.83x
P/B Ratio (Annual)0.73x
Pretax Margin (TTM)-21.70%
Book Value / Share (Annual)$35.78
Price vs S&P 500 (13W)-43.27%
Beta0.97x
P/FCF (Annual)100.05x
Revenue / Share (TTM)$10.41
ROE (TTM)-5.40%
52-Week Low$13.46
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Health Services(20)
| Symbol | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|
FLGTFulgent Genetics, Inc. Common Stock | — | 13.83% | -31.31% | -5.40% | $16.13 |
NTRANatera, Inc. Common Stock | — | 35.90% | -13.44% | -15.28% | $196.11 |
LHLabcorp Holdings Inc. | 25.08x | 7.25% | 9.92% | 10.28% | $266.36 |
DGXQuest Diagnostics Inc. | 21.24x | 11.78% | 14.10% | 13.88% | $191.46 |
EXASExact Sciences Corp | — | 17.69% | -6.35% | -8.51% | $104.91 |
GHGuardant Health, Inc. Common Stock | — | 32.88% | -45.02% | -246.60% | $85.70 |
RDNTRadNet, Inc. Common Stock | 1779.27x | 11.51% | 3.04% | -1.88% | $60.09 |
VCYTVeracyte, Inc. | 40.04x | 16.01% | 11.17% | 5.33% | $33.03 |
GRALGRAIL, Inc. Common Stock | — | 17.18% | -381.98% | -17.11% | $49.47 |
CDNACareDx, Inc. | 18.34x | 13.79% | -8.10% | -6.47% | $22.42 |
FTREFortrea Holdings Inc. Common Stock | — | 1.00% | -32.04% | -152.17% | $10.09 |
About
Fulgent Genetics is a genetic testing company providing physicians with diagnostic laboratory services and clinical interpretation to guide patient treatment. The company's core laboratory services segment, which generates the majority of revenue, offers technical testing and professional interpretation by licensed physicians. The company also operates a therapeutic development business focused on developing cancer drug candidates, with operations primarily in the United States and select international markets.